Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era (vol 7, pg 1409, 2014)

被引:2
作者
Berger, J. L.
Smith, A.
Zorn, K. K.
机构
关键词
D O I
10.2147/OTT.S80592
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
引用
收藏
页码:593 / 593
页数:1
相关论文
共 1 条
[1]   Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [J].
Berger, Jessica L. ;
Smith, Ashlee ;
Zorn, Kristin K. ;
Sukumvanich, Paniti ;
Olawaiye, Alexander B. ;
Kelley, Joseph ;
Krivak, Thomas C. p .
ONCOTARGETS AND THERAPY, 2014, 7 :1409-1413